Results 1 to 10 of about 35,836 (258)

Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma

Pharmacological Research
Immune checkpoint inhibitors (ICIs) are essential for urothelial carcinoma (UC) treatment. Fibroblast growth factor receptor (FGFR) alterations, as common oncogenic drivers in UC, have been reported to drive T cell depletion of UC immune microenvironment
Yuxuan Song, Shan Jiang, Yun Peng, Caipeng Qin, Yiqing Du, Tao Xu   +5 more
doaj   +2 more sources

Bilateral Subretinal Fluid Accumulation during Erdafitinib Therapy

TNOA Journal of Ophthalmic Science and Research
Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of ...
Rajneesh Singh, Nipun Bagrecha, Suresh K. Pandey, Deepesh Chabblani   +3 more
doaj   +1 more source

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma

International Journal of Retina and Vitreous, 2021
Background Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous
Oleg Alekseev, Effy Ojuok, Scott Cousins
doaj   +1 more source

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells

Frontiers in Oncology, 2021
Deregulation of fibroblast growth factor receptors (FGFRs) signaling, as a result of FGFR amplification, chromosomal translocation, or mutations, is involved in both initiation and progression of a wide range of human cancers. Clinical data demonstrating
Kamila Kitowska, Monika Gorska-Arcisz, Dima Antoun, Izabela Zarczynska, Dominika Czaplinska, Adrian Szczepaniak, Andrzej C. Skladanowski, Maciej Wieczorek, Aleksandra Stanczak, Monika Skupinska, Rafal Sadej   +10 more
doaj   +1 more source

Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer

Biomolecules, 2022
Recently, FGFR inhibitors have been highlighted as promising targeted drugs due to the high prevalence of FGFR1 amplification in cancer patients. Although various potential biomarkers for FGFR inhibitors have been suggested, their functional effects have
Jonghoon Lee, Sea Rom Choi, Kwang-Hyun Cho   +2 more
doaj   +1 more source

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Acta Pharmaceutica
The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment.
Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar   +10 more
doaj   +1 more source

Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. [PDF]

PLoS ONE, 2012
Fibroblast Growth Factor receptor (FGFR) activity plays crucial roles in tumor growth and patient survival. However, FGF (Fibroblast Growth Factor) signaling as a target for cancer therapy has been under-investigated compared to other receptor tyrosine ...
Frédéric Larrieu-Lahargue, Alana L Welm, Marion Bouchecareilh, Kari Alitalo, Dean Y Li, Andreas Bikfalvi, Patrick Auguste   +6 more
doaj   +1 more source

Unraveling the FGFR–RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose

Acta Pharmaceutica Sinica B
Fibroblast growth factor receptor (FGFR) signaling is a pivotal regulator of tumor progression, driving cell proliferation, survival, metastasis, and therapeutic resistance across diverse cancer types.
Xuquan Xian, Ruyi Gong, Shunzi Rong, Zhihao Zhang, Fengtong Jia, Lin Li, Zhengguo Chen, Beatrice Eymin, Tao Jia   +8 more
doaj   +1 more source

Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients

Cancer Biology & Medicine, 2016
The fibroblast growth factor receptor (FGFR) family plays important roles in regulating cell growth, proliferation, survival, differentiation and angiogenesis.
Wen-Ya Zhou, Hong Zheng, Xiao-Ling Du, Ji-Long Yang   +3 more
doaj   +1 more source

Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer

Frontiers in Oncology, 2022
Fibroblast growth factor receptor (FGFR) inhibitors (FGFRis) are a potential therapeutic option for squamous non-small cell lung cancer (Sq-NSCLC).
Joanna Moes-Sosnowska, Joanna Chorostowska-Wynimko   +1 more
doaj   +1 more source